Dr. Rudin on Expansion of Immunotherapy in Lung Cancer

Video

In Partnership With:

Charles M. Rudin, MD, PhD, the Sylvia Hassenfeld Chair in Lung Cancer Research, chief, Thoracic Oncology, co-director, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the current landscape of immunotherapy in lung cancer and how he expects the treatment to expand.

Charles M. Rudin, MD, PhD, the Sylvia Hassenfeld Chair in Lung Cancer Research, chief, Thoracic Oncology, co-director, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the current landscape of immunotherapy in lung cancer and how he expects the treatment to expand.

Immunotherapy has been a transformative treatment in lung cancer in many ways, but it does not work in all patients, says Rudin. In terms of durable responses, immunotherapy works in a minority of patients. Rudin wants to expand the utility of immunotherapy to allow more patients to experience the durable, long-term benefit that some patients are able to achieve.

There are a number of strategies that are in development to try to augment the efficacy of immunotherapy to induce responses in tumors that would otherwise not be responsive to these agents. Rudin is particularly interested in the use of oncolytic viruses to induce immunoreactivity within tumors. Since the immune system is designed to fight infections, creating a local infection within the tumor microenvironment is, in some ways, an ideal way to fight the tumor, explains Rudin.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,